Two TCRs that are unique to the KRAS G12V-9 peptide and modified TCR-T cells that showed specific responses to different types of tumor cells with the KRAS-G12V mutation have been developed. When combined with anti-PD-1 antibodies, the 1-2C TCR-T cells demonstrated enhanced anti-tumor potency and successfully suppressed tumors in vivo. Here, KRAS is linked to neoplasm.